)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Eris Lifesciences
Eris Lifesciences (ERIS) investor relations material
Eris Lifesciences Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary26 Oct, 2026
Executive summary
Q2 FY27 consolidated revenue was ₹892.37 crore, up 12.6% YoY; net profit was ₹187.14 crore, up 39.2%, or ₹158 crore and up 17.5% on an adjusted basis.
H1 revenue was ₹1,765.62 crore, up 12.8%; domestic branded formulations grew 14.2%.
H2 EBITDA margin outlook improved to 36%; Bhopal ramp-up and gross-margin recovery are key supports, while Swiss recovery depends on GMP progress.
Financial highlights
H1 EBITDA was ₹606 crore, up 7.2%, and net profit was ₹330.46 crore, up 27.3%; Q2 consolidated EBITDA grew 7.3% YoY.
Q2 consolidated gross margin was 74.7% vs 74.5% YoY; EBITDA margin was 34.7% vs 36.4%.
Q2 basic EPS was ₹13.26; H1 basic EPS was ₹23.54, not annualised.
H1 operating cash flow was ₹637.13 crore, equal to 105% of EBITDA; H1 capex was ₹220.40 crore.
Higher other expenses, up 27%, reflected seasonal launch spending, product development, filings and regulatory costs.
Outlook and guidance
Domestic growth guidance remains 300 bps above the market; management sees IPM growth of 11%-12% next year.
Swiss Parenterals FY27 revenue is expected within ±5% of last year, with EBITDA margin around 25%.
FY27 effective tax rate is expected at 20%-21%, with a similar level next year.
Management expects 1-3 insulin analog launches next year; FY27 launches are largely on track, with a cardiac product due imminently.
FY27 capex of ~₹100 crore remained for H2; the capex cycle is expected to wind down by FY27-end.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Eris Lifesciences
- FY17 growth accelerated as chronic therapies and strategic acquisitions expanded the business.ERIS
Q4 16/17 - FY18 growth and margin gains advanced alongside major portfolio acquisitions and regulatory risks.ERISQ4 17/18
- Sales grew 15%, but lower margins and channel inventory correction weighed on earnings.ERISQ4 18/19
- Revenue rose 9.4% as investment supported growth, despite COVID disruption and margin pressure.ERISQ4 19/20
- FY21 growth and cash generation advanced despite pandemic disruption and acute-market weakness.ERISQ4 20/21
- FY22 growth and cash generation fund expansion into insulin, dermatology and new launches.ERISQ4 21/22
- Acquisitions lifted sales and diversified therapies, while weighing on margins and earnings.ERISQ4 22/23
- Q1 FY27 saw 13% revenue and 14.5% PAT growth, strong DBF and insulin/GLP-1 gains, and key acquisitions.ERISQ1 26/27
- Q1 revenue up 54% and EBITDA up 47%, with strong acquisitions but margin pressure.ERISQ1 24/25
Next Eris Lifesciences earnings date
Q3 26/2712 Feb, 2027
Eris Lifesciences
Next Eris Lifesciences earnings date
Q3 26/2712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Eris Lifesciences Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and marketing of branded formulations. The company focuses on therapeutic areas such as cardiovascular, diabetes, neurology, gastroenterology, and dermatology. It primarily caters to the domestic market, targeting healthcare professionals and patients through its portfolio of prescription medicines. The company is headquartered in Ahmedabad, India, and its shares are listed on the NSE and BSE.